Drug
Pembrolizumab Enfortumab Vedotin
Pembrolizumab Enfortumab Vedotin: highest development phase Phase 2, developed by Natera. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Natera
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pembrolizumab & Enfortumab Vedotin (PEV) NCT07183319 | Phase 2 | Urothelial Carcinoma |
Latest
No recent events.
Follow Pembrolizumab Enfortumab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.